Race Oncology Ltd has released a press release.
Race secures fifth US patent for Zantrene
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Preclinical & Clinical Programs Update
- Zantrene highly effective in Melanoma preclinical study
- First Patient Dosed in Phase 1b/2 AML Trial
- Race executes Israel AML Phase 2 Trial Contract
- Race Executes Key Contract for Israel Phase 2 AML Trial
Later from Racura Oncology
- Race secures sixth US patent for Zantrene
- University of Wollongong R&D Collaboration
- Breakthrough Zantrene Heart Protection Discovery
- AGM Presentations
- Race Oncology Share Purchase Plan
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology